Molecular Partners Ag -adr (MOLN)

$4.75

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $4.73
    $5.35
    $4.75
    downward going graph

    0.42%

    Downside

    Day's Volatility :11.59%

    Upside

    11.21%

    downward going graph
  • $3.32
    $12.70
    $4.75
    downward going graph

    30.11%

    Downside

    52 Weeks Volatility :73.86%

    Upside

    62.6%

    downward going graph

Returns

PeriodMolecular Partners Ag -adrSector (Health Care)Index (Russel 2000)
3 Months
-29.1%
3.7%
0.0%
6 Months
23.06%
8.3%
0.0%
1 Year
9.17%
17.1%
0.0%
3 Years
-75.54%
21.3%
-20.3%

Highlights

Market Capitalization
162.9M
Book Value
$4.69
Earnings Per Share (EPS)
-2.05
Wall Street Target Price
13.5
Profit Margin
0.0%
Operating Margin TTM
-1030.05%
Return On Assets TTM
-19.31%
Return On Equity TTM
-31.88%
Revenue TTM
7.9M
Revenue Per Share TTM
0.24
Quarterly Revenue Growth YOY
273.7%
Gross Profit TTM
138.9M
EBITDA
-61.0M
Diluted Eps TTM
-2.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.02
EPS Estimate Next Year
-2.15
EPS Estimate Current Quarter
-1.49
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    9%Buy
    27%Hold
    63%Sell
Based on 11 Wall street analysts offering stock ratings for Molecular Partners Ag -adr(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
3
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 184.21%

Current $4.75
Target $13.50

Company Financials

FY18Y/Y Change
Revenue
10.4M
↓ 48.27%
Net Income
-37.3M
↑ 45.64%
Net Profit Margin
-357.66%
↓ 230.61%
FY19Y/Y Change
Revenue
20.7M
↑ 96.84%
Net Income
-36.9M
↓ 2.02%
Net Profit Margin
-178.03%
↑ 179.63%
FY20Y/Y Change
Revenue
10.5M
↓ 54.16%
Net Income
-70.6M
↑ 72.96%
Net Profit Margin
-671.7%
↓ 493.67%
FY21Y/Y Change
Revenue
10.1M
↓ 0.15%
Net Income
-69.3M
↑ 1.63%
Net Profit Margin
-683.65%
↓ 11.95%
FY22Y/Y Change
Revenue
203.1M
↑ 1931.68%
Net Income
126.3M
↓ 284.77%
Net Profit Margin
62.17%
↑ 745.82%
FY23Y/Y Change
Revenue
8.1M
↓ 96.29%
Net Income
-71.7M
↓ 152.59%
Net Profit Margin
-880.7%
↓ 942.87%
Q1 FY23Q/Q Change
Revenue
3.3M
↑ 13.26%
Net Income
-16.5M
↓ 23.02%
Net Profit Margin
-502.39%
↑ 236.75%
Q2 FY23Q/Q Change
Revenue
460.9K
↓ 86.39%
Net Income
-17.8M
↑ 4.33%
Net Profit Margin
-3.9K%
↓ 3349.9%
Q3 FY23Q/Q Change
Revenue
2.8M
↑ 512.29%
Net Income
-12.7M
↓ 28.45%
Net Profit Margin
-450.18%
↑ 3402.11%
Q4 FY23Q/Q Change
Revenue
1.2M
↓ 59.39%
Net Income
-22.9M
↑ 72.92%
Net Profit Margin
-1.9K%
↓ 1466.49%
Q1 FY24Q/Q Change
Revenue
3.1M
↑ 165.31%
Net Income
-12.7M
↓ 42.75%
Net Profit Margin
-413.62%
↑ 1503.05%
Q2 FY24Q/Q Change
Revenue
1.7M
↓ 43.35%
Net Income
-16.9M
↑ 33.17%
Net Profit Margin
-972.4%
↓ 558.78%
FY18Y/Y Change
Total Assets
156.4M
↑ 7.43%
Total Liabilities
64.0M
↑ 129.12%
FY19Y/Y Change
Total Assets
106.8M
↓ 32.37%
Total Liabilities
51.7M
↓ 19.95%
FY20Y/Y Change
Total Assets
210.9M
↑ 78.73%
Total Liabilities
90.3M
↑ 58.13%
FY21Y/Y Change
Total Assets
187.6M
↓ 7.93%
Total Liabilities
71.0M
↓ 18.61%
FY22Y/Y Change
Total Assets
281.0M
↑ 51.89%
Total Liabilities
29.0M
↓ 58.56%
FY23Y/Y Change
Total Assets
229.5M
↓ 24.37%
Total Liabilities
25.4M
↓ 19.08%
Q1 FY23Q/Q Change
Total Assets
264.0M
↓ 6.76%
Total Liabilities
24.2M
↓ 17.43%
Q2 FY23Q/Q Change
Total Assets
256.0M
↓ 5.74%
Total Liabilities
27.2M
↑ 9.59%
Q3 FY23Q/Q Change
Total Assets
242.7M
↓ 5.37%
Total Liabilities
24.4M
↓ 10.63%
Q4 FY23Q/Q Change
Total Assets
229.5M
↓ 9.06%
Total Liabilities
25.4M
↑ 0.06%
Q1 FY24Q/Q Change
Total Assets
208.8M
↓ 6.43%
Total Liabilities
19.2M
↓ 22.18%
Q2 FY24Q/Q Change
Total Assets
190.9M
↓ 8.08%
Total Liabilities
16.8M
↓ 11.79%
FY18Y/Y Change
Operating Cash Flow
-42.8M
↑ 6.13%
Investing Cash Flow
9.7M
↓ 53.93%
Financing Cash Flow
395.1K
↓ 50.94%
FY19Y/Y Change
Operating Cash Flow
-1.2M
↓ 97.2%
Investing Cash Flow
-20.2M
↓ 306.35%
Financing Cash Flow
-230.9K
↓ 157.91%
FY20Y/Y Change
Operating Cash Flow
-32.6M
↑ 2337.59%
Investing Cash Flow
-24.5M
↑ 9.63%
Financing Cash Flow
127.3M
↓ 49968.72%
FY21Y/Y Change
Operating Cash Flow
-98.8M
↑ 213.81%
Investing Cash Flow
-24.2M
↑ 2.26%
Financing Cash Flow
54.9M
↓ 55.32%
FY22Y/Y Change
Operating Cash Flow
127.1M
↓ 230.36%
Investing Cash Flow
-108.4M
↑ 354.74%
Financing Cash Flow
-1.7M
↓ 103.1%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.9M
↑ 15.97%
Investing Cash Flow
4.4M
↓ 88.76%
Financing Cash Flow
-320.7K
↓ 0.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.7M
↓ 19.72%
Investing Cash Flow
4.5M
↑ 0.0%
Financing Cash Flow
-304.3K
↓ 7.74%
Q3 FY23Q/Q Change
Operating Cash Flow
-14.7M
↓ 0.67%
Investing Cash Flow
19.8M
↑ 340.5%
Financing Cash Flow
-331.6K
↑ 8.76%

Technicals Summary

Sell

Neutral

Buy

Molecular Partners Ag -adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Molecular Partners Ag -adr
Molecular Partners Ag -adr
-13.64%
23.06%
9.17%
-75.54%
-75.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.48%
8.55%
19.49%
82.88%
232.15%
Novo Nordisk A/s
Novo Nordisk A/s
-13.09%
-6.28%
18.91%
138.88%
358.83%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.38%
83.19%
66.02%
36.22%
252.82%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.3%
18.97%
30.36%
165.15%
176.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Molecular Partners Ag -adr
Molecular Partners Ag -adr
1.71
NA
NA
-2.02
-0.32
-0.19
NA
4.69
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Molecular Partners Ag -adr
Molecular Partners Ag -adr
Sell
$162.9M
-75.09%
1.71
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
232.15%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
358.83%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.8B
252.82%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
176.17%
32.84
-4.74%

Insights on Molecular Partners Ag -adr

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.73M → 1.55M (in $), with an average decrease of 43.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.32M → -15.08M (in $), with an average decrease of 33.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.0% return, outperforming this stock by 56.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 36.2% return, outperforming this stock by 111.7%

Institutional Holdings

  • Bvf Inc

    1.34%

  • Suvretta Capital Management, LLC

    1.21%

  • OLD MISSION CAPITAL LLC

    0.03%

  • UBS Group AG

    0.01%

  • TANG CAPITAL MANAGEMENT LLC

    0.01%

Company Information

Organization
Molecular Partners Ag -adr
Employees
161
CEO
Dr. Patrick Amstutz Ph.D.
Industry
Services

Discover More

FAQs